These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study.
    Author: Andersson L, Berlin T, Boman J, Collste L, Edsmyr F, Esposti PL, Gustafsson H, Hedlund PO, Hultgren L, Leander G, Nordle O, Norlén H, Tillegård P.
    Journal: Scand J Urol Nephrol Suppl; 1980; 55():143-5. PubMed ID: 6259722.
    Abstract:
    In a prospective randomized multicenter trial patients with highly or moderately differentiated prostatic carcinoma, previously untreated, were allotted either to oral Estramustine phosphate or to intramuscular polyestradiol phosphate plus oral ethinyl estradiol. As regards frequency and duration of tumour remission there was no statistical difference between the two groups. Nor did they differ significantly with respect to adverse reactions. This is an interim report and will be followed later on by a final evaluation.
    [Abstract] [Full Text] [Related] [New Search]